THNR ETF (Amplify Weight Loss Drug & Treatment ETF) is managed by Amplify ETFs with $4.1M in net assets. THNR expense ratio is 0.59%, holding 23 positions across sectors including Health Care, Unknown, Financials. Inception date: 2024-05-21.

THNR performance shows a YTD return of -5.13%. The 1-year return is 13.97%. THNR dividend yield stands at 1.66%, paid annually.

THNR top holdings include Novo Nordisk A/S Cl B (11.9%), Eli Lilly and Co. (11.6%), Regeneron Pharmaceuticals, Inc. (6.8%), Amgen Inc. (6.3%), Chugai Pharmaceutical Co., Ltd (6.0%). View all THNR holdings, sector breakdown, or dividend history.

THNR can be compared against other funds using the overlap calculator or side-by-side comparison tool. THNR alternatives are available via the screener, along with tax-loss harvesting opportunities.